Thursday, February 03, 2022 6:42:11 PM
Effective February 1, 2022, the Chief Executive Officer, Chief Financial Officer and Chief Medical Officer of HOOKIPA Pharma Inc. (the “Company”), along with other members of the Company’s executive team (the “Executive Team”), waived a portion of their base salaries, for the six months ending June 30, 2022. In exchange for such waiver of salary, each such officer received that number of shares of the Company’s fully vested common stock having a value equal to their foregone salary (determined based on a fixed price of $3.00 per share), resulting in the issuance of an aggregate of 112,549 shares of common stock. Pursuant to such waiver, the Company’s Chief Executive Officer, Joern Aldag, waived 50 percent of his base salary for the six months ending June 30, 2022 in exchange for a commensurate stock grant of 47,824 fully vested shares of common stock. The Company’s Chief Financial Officer, Reinhard Kandera, and Chief Medical Officer, Igor Matushansky, each waived 20 percent of their base salaries for the six months ending June 30, 2022 in exchange for a commensurate stock grant of 14,056 and 14,933 fully vested shares of common stock, respectively. All of the officers noted above, along with other members of the Executive Team, also received 50 percent of their 2021 annual bonus in the form of a stock option grant, determined based on a value of $3.00 per share, resulting in the issuance of a total number of 145,071 options. Messrs. Aldag and Kandera and Dr. Matushansky each received 39,853, 23,427 and 24,888 options, respectively. The granted options have an exercise price of $1.50 per share, the closing price of the Company’s common stock on January 31, 2022. https://seekingalpha.com/filing/6173820
Recent HOOK News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:04:58 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 09:27:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:15:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:32:12 PM
- HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 08/08/2024 08:30:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/02/2024 10:38:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:08:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:17:16 PM
- HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 • GlobeNewswire Inc. • 07/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 11:00:16 AM
- HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split • GlobeNewswire Inc. • 07/08/2024 11:01:00 AM
- HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV • GlobeNewswire Inc. • 07/01/2024 08:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:03:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:15:13 PM
- HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 06/04/2024 05:00:44 PM
- HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 05/30/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:05:13 PM
- HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:04:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:03:13 AM
- HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/09/2024 11:01:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM